The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
In this video, Asfand Yar Cheema, MD, Cleveland Clinic, Cleveland, OH, shares insights into the clinical outcomes of patients with polycythemia vera (PV) and myelodysplastic syndromes (MDS) treated with GLP-1 agonists. He discusses the pathways involved and the mechanism of action of these agents, and further highlights potential future applications. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
